8-K: Recursion Pharmaceuticals Announces First Quarter 2024 Results and Strategic Updates

Recursion Pharmaceuticals reported its Q1 2024 financial results, highlighted by progress in clinical trials, platform expansion, and strategic partnerships.

Summary

• Recursion Pharmaceuticals announced its first quarter 2024 financial results, with total revenue of $13.8 million, up from $12.1 million in Q1 2023, primarily due to increased revenue from the Roche partnership.
• Research and development expenses increased to $67.6 million, compared to $46.7 million in the same period last year, reflecting the expansion of the platform and clinical trial advancements.
• General and administrative expenses rose to $31.4 million, up from $22.9 million in Q1 2023, due to increased salaries and software costs.
• The company reported a net loss of $91.4 million for the quarter, compared to a net loss of $65.3 million in Q1 2023.
• Net cash used in operating activities was $102.3 million for the quarter, compared to $73.3 million in the same period last year, due to higher operating costs and annual bonus payments.
• Cash and cash equivalents totaled $296.3 million as of March 31, 2024.
• The company is on track to read out multiple Phase 2 clinical trials in the coming quarters, starting in Q3 2024.
• Recursion has completed performance benchmarking on BioHive-2, its next-generation supercomputer, which is expected to be among the top 50 globally.
• The company has scaled its transcriptomics technology to over 1 million transcriptomes and is developing a whole-genome knockout transcriptomics map.
• A multi-year agreement with Helix was established to access de-identified health records for AI model training.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is significant progress in clinical trials, platform development, and strategic partnerships, the increased net loss and cash burn are concerning. The company's future outlook is positive, but the financial results temper the overall sentiment.

Positives

• Revenue increased year-over-year, driven by the Roche partnership.
• The company is making significant progress in its clinical pipeline with multiple Phase 2 readouts expected in the near term.
• The BioHive-2 supercomputer is nearing completion and is expected to be a powerful asset.
• The company is expanding its data generation capabilities with the scaling of its transcriptomics technology.
• Strategic partnerships with Helix, Roche, Bayer, Tempus, and NVIDIA are progressing well.
• The company has appointed a new Chief R&D Officer and Chief Commercialization Officer, Dr. Najat Khan, who also joined the Board of Directors.
• Recursion is expanding its global presence with a new office in London.

Negatives

• The company's net loss increased significantly compared to the same quarter last year.
• Research and development expenses and general and administrative expenses have increased substantially.
• Net cash used in operating activities increased compared to both the previous quarter and the same quarter last year.
• A material weakness in internal control over financial reporting related to revenue recognition was identified in 2023 and is still being remediated.

Risks

• The company faces risks inherent in pharmaceutical research and development, including clinical trial failures.
• There are risks associated with obtaining regulatory approvals and commercializing drug candidates.
• The company's ability to obtain financing for development activities is a risk.
• Cyberattacks or other disruptions to technology systems pose a risk.
• The company's ability to attract, motivate, and retain key employees is a risk.
• Inflation and other macroeconomic issues could impact the company's performance.

Future Outlook

The company anticipates multiple value catalysts in the near term, including clinical trial readouts, partnership option exercises, new partnerships, and interest in its data and technology solutions. They expect to initiate a Phase 2 study for C. difficile infection in 2024 and submit an IND for RBM39 in H2 2024. The company also expects to complete the whole-genome knockout transcriptomics map in the coming quarters.

Management Comments

• Chris Gibson, Ph.D., Co-founder and CEO of Recursion, stated that the company is excited about the multiple upcoming value catalysts.
• Chris Gibson noted the increasing understanding and appetite for combining large-scale computing resources with large-scale data generation.
• The company is thrilled to welcome Dr. Najat Khan to Recursion to help lead R&D and commercialization efforts.

Industry Context

This announcement highlights Recursion's position as a leading TechBio company, combining advanced technology with drug discovery. The company's focus on AI, supercomputing, and large-scale data generation aligns with the broader industry trend of leveraging technology to accelerate drug development. The partnerships with major players in both the biopharma and tech industries underscore the growing importance of collaboration in this space.

Comparison to Industry Standards

• Recursion's approach to drug discovery, which combines large-scale data generation with AI and supercomputing, is unique compared to traditional pharmaceutical companies.
• The company's BioHive-2 supercomputer is expected to be one of the most powerful in the biopharma industry, potentially placing it in the top 50 globally, which is a significant differentiator.
• The company's ability to generate and analyze vast amounts of biological data, including over 1 million transcriptomes, is a significant advantage compared to many other companies in the space.
• Recursion's partnerships with companies like Roche, Bayer, and Tempus are indicative of its ability to attract industry-leading collaborations, which is a key factor in its growth strategy.
• The company's focus on rare diseases and precision oncology aligns with the industry's growing interest in targeted therapies and personalized medicine.
• Compared to industry averages, Recursion believes its approach enables it to identify low-viability programs earlier, spend less per program, and rapidly advance programs to a validated lead candidate.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and cash burn, but encouraged by the progress in clinical trials and platform development.
• Employees may be motivated by the company's growth and strategic partnerships, but also aware of the financial challenges.
• Customers and partners may be interested in the company's advancements in drug discovery and technology.
• Suppliers and creditors may be impacted by the company's financial performance and cash flow.

Next Steps

• The company expects to share Phase 2 data for the SYCAMORE clinical trial in Q3 2024.
• The company expects to share Phase 2 safety and preliminary efficacy data for the POPLAR clinical trial in Q4 2024.
• The company expects to share Phase 2 safety and preliminary efficacy data for the TUPELO and LILAC clinical trials in H1 2025.
• The company plans to initiate a Phase 2 study for C. difficile infection in 2024.
• The company expects to submit an IND for RBM39 in H2 2024.
• The company plans to complete the whole-genome knockout transcriptomics map in the coming quarters.

Key Dates

Keywords

drug discovery, clinical trials, AI, supercomputer, transcriptomics, partnerships, oncology, rare diseases, TechBio, data science